BRAF和/或MEK抑制剂治疗后的周围神经病:一项药物警戒研究
患者主要表现为两种临床表型:6例为长度依赖性轴索性多神经病,症状多为感觉性且累及下肢;9例为脱髓鞘性多神经根神经病,症状累及四肢,包括感觉减退、无力和共济失调,4例累及脑神经。多数脱髓鞘性患者接受静脉免疫球蛋白或糖皮质激素治疗,转归不一;1例再次挑战不同BRAF/MEK抑制剂组合后症状快速复发。
要点
- BRAF/MEK抑制剂治疗可能诱发周围神经病,需警惕感觉异常、无力或共济失调。
- 主要表型为长度依赖性轴索性多神经病和脱髓鞘性多神经根神经病。
- 脱髓鞘性表型常用IVIG或糖皮质激素,但转归不一,再挑战可能快速复发。
核心结论
- 接受BRAF抑制剂和/或MEK抑制剂治疗的患者可能发生治疗诱发的周围神经病。
- 主要表现为两种表型:对称性、轴索性、长度依赖性多神经病和脱髓鞘性多神经根神经病。
主要发现
- 6例患者表现为长度依赖性轴索性多神经病,症状多为感觉性且累及下肢,管理和转归不一。
- 9例患者发展为脱髓鞘性多神经根神经病,症状累及四肢,包括感觉减退、无力和共济失调,4例累及脑神经。
- 多数脱髓鞘性患者接受静脉免疫球蛋白或糖皮质激素治疗,转归不一;1例再次挑战不同BRAF/MEK抑制剂组合后症状快速复发。
临床怎么用
- 临床用药期间应监测周围神经病症状,如新发感觉异常、无力或共济失调,及时识别并处理。
- 对疑似病例需鉴别轴索性与脱髓鞘性表型,脱髓鞘性可考虑免疫调节治疗,但需注意再挑战风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reports suggested the potential occurrence of peripheral neuropathies (PN) in patients treated with BRAF (BRAFi) and/or MEK inhibitors (MEKi) for BRAF-activated tumours. We aimed to better characterize these PN. We queried the French pharmacovigilance database for all cases of PN attributed to BRAFi and/or MEKi. Fifteen patients were identified. Two main clinical PN phenotypes were seen. Six patients presented a length-dependent, axonal polyneuropathy: symptoms were mostly sensory and affecting the lower limbs; management and outcome were variable. Nine patients developed a demyelinating polyradiculoneuropathy: symptoms affected the four limbs and included hypoesthesia, weakness and ataxia; cranial nerves were involved in four cases; most patients received intravenous immunoglobulins or glucocorticoids, with variable outcome; one patient was rechallenged with a different BRAFi/MEKi combination with a rapid relapse in symptoms. In conclusion, patients under BRAFi/MEKi therapy may develop treatment-induced PN. Two main phenotypes can occur: a symmetric, axonal, length-dependent polyneuropathy and a demyelinating polyradiculoneuropathy.
引用
- Picca A, Birzu C, Berzero G, et al. Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study. Br J Clin Pharmacol. 2022. PMID: 36028463. doi:10.1111/bcp.15513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。